Allena Pharmaceuticals
ALNA
ALNA was delisted on the 7th of September, 2022.
25 hedge funds and large institutions have $1.71M invested in Allena Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 8 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
8% less capital invested
Capital invested by funds: $1.86M → $1.71M (-$156K)
11% less funds holding
Funds holding: 28 → 25 (-3)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$194K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$55.3K |
| 3 |
Millennium Management
New York
|
+$26.9K |
| 4 |
Citigroup
New York
|
+$26.7K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$236K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$29K |
| 3 |
VF
Virtu Financial
New York
|
-$10K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$9K |
| 5 |
BlackRock
New York
|
-$4.76K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
26
Virtu Financial
New York
| – | -$10K | -43,414 | Closed |
|
|
27
Citadel Advisors
Miami,
Florida
| – | -$9K | -37,613 | Closed |
|
28
Jane Street
New York
| – | -$3K | -12,558 | Closed |
|
29
Morgan Stanley
New York
| – | -$1.79K | -11,539 | -100% |
|
|
RA
30
RFG Advisory
Birmingham,
Alabama
| – | -$3K | -11,000 | Closed |
|
31
Victory Capital Management
San Antonio,
Texas
| – | -$2K | -10,745 | Closed |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| – | -$2K | -10,645 | Closed |
|
33
Wells Fargo
San Francisco,
California
| – | +$13 | +85 | +3% |
|
ALNA Hedge Fund Activity: Q2 2022 in Review
25 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Allena Pharmaceuticals (ALNA) for Q2 2022, worth a combined $1.71M — down 8.4% from $1.86M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ALNA and 5 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 8 added.
The largest buyer was Acadian Asset Management, opening a new position worth an estimated $194K. The largest seller was Frazier Management, exiting entirely with an estimated $236K sold.
- 25 institutional investors held Allena Pharmaceuticals (ALNA) as of Q2 2022, down from 28 in Q1 2022.
- Funds reported $1.71M of Allena Pharmaceuticals stock for Q2 2022, down 8.4% quarter-over-quarter.
- 5 funds opened new Allena Pharmaceuticals positions in Q2 2022 and 8 closed out, a net change of -3 holders.
- The largest Allena Pharmaceuticals buyer in Q2 2022 was Acadian Asset Management, an estimated $194K added.
- The largest Allena Pharmaceuticals seller in Q2 2022 was Frazier Management, an estimated $236K sold.
Based on aggregated 13F filings for Q2 2022.